For example, PD-L1 for monitoring patients undergoing immunotherapy (10), androgen receptor splice variant 7 (ARv7) for emergence of therapeutic resistance in prostate cancer (31), and assessing biomarkers such as EGFR, HER2 or PD-L1 in esophageal cancer (36). This evidence concerns the gene CD274 and prostate carcinoma.